Nucleome Patents

Patent portfolio assigned to Nucleome (verified via public assignee records). UK (Oxford) biotech (Nucleome Therapeutics), University of Oxford spin-out; 3D-genomics drug discovery using Micro Capture-C (MCC) + ML for non-coding genome, autoimmune-disease focus (lead NTP464). has_patents true per fetched company/BioEscalator press stating 'several new patents granted in 2025 protect MCC and Nucleome's proprietary Variant Functional Validation (VFV) technologies'; exact count not visible (Google Patents blocked this task), estimate left 0. No named customers/competitors in sources (early-stage; Pfizer, J&J/JJDC and M Ventures are investors, not customers).